Monte Rosa Therapeutics Insider Sells Over $100K in Shares

Philip Nickson, a company insider, disposed of nearly 6,000 shares of the biotech firm's stock.

Apr. 10, 2026 at 9:10pm

Got story updates? Submit your updates here. ›

An extreme close-up of a tangle of industrial gears and machinery in shades of grey and blue, conceptually representing the intricate financial infrastructure and institutional power of a biotechnology company.An insider's sale of shares in a biotech firm exposes the complex financial machinery powering the industry.Cambridge Today

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Philip Nickson sold 5,845 shares of the company's stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $17.69, for a total transaction value of $103,398.05. Following the sale, Nickson still owns 55,000 shares in the company, valued at approximately $972,950.

Why it matters

Insider transactions, especially sales, can provide insight into management's views on a company's prospects. While a single transaction does not necessarily indicate broader sentiment, ongoing insider selling could signal potential concerns about the business that outside investors should monitor.

The details

The sale represented a 9.61% decrease in Nickson's position. The transaction was disclosed in a filing with the Securities and Exchange Commission.

  • The shares were sold on Thursday, April 9th, 2026.

The players

Philip Nickson

An insider at Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE).

Monte Rosa Therapeutics, Inc.

A biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence.

Got photos? Submit your photos here. ›

The takeaway

While a single insider transaction does not necessarily indicate broader concerns, ongoing insider selling could be a signal that investors should monitor the company's prospects more closely.